ATH — Alterity Therapeutics Share News
0.000.00%
Last trade - 00:00- AU$1.96m
- -AU$47.14m
- AU$0.45m
Brief: Alterity Therapeutics Appoints Abby Macnish Niven As Chief Financial Officer
Seeks Trading Halt
Brief: Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial As Planned After Third Review
Brief: Alterity Therapeutics HY Loss Attributable A$6.5 Million
Brief: Alterity Therapeutics Raises A$3.25 Million In Placement
Brief: Alterity Therapeutics Seeks Trading Halt
Brief: Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial As Planned After Second Review
Brief: Alterity Therapeutics Says Ath434-201 Study To Complete In November 2024
Brief: Alterity Therapeutics Appoints Phillip Hains As Chief Financial Officer
Brief: Alterity Therapeutics Reports Positive Efficacy Data For Ath434 In A Primate Model Of Parkinson's Disease
Australia's Alterity Therapeutics hits record low on discounted placement
Brief: Alterity Therapeutics Received Binding Commitments For A Capital Raising Of A$4.8M
Brief: Alterity Therapeutics Seeks Trading Halt
Brief: Alterity Therapeutics Posts FY Net Loss After Tax Attributable A$13.8 Mln
Brief: Alterity Therapeutics Receives A $4.74 Million Research & Development Tax Incentive Refund
Brief: Alterity Therapeutics Says ATH434-201 Trial Remains On Track
Alterity's US-listed shares rise as new study begins in rare Parkinsonian disorder drug
Brief: Alterity Therapeutics Enrolls First Patient In The United Kingdom In Ath434 Phase 2 Clinical Trial In Multiple System Atrophy
Brief: Alterity Therapeutics Says Composition Of Matter Patent Granted